ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2022
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.
Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.PharmacoEconomics - open · 2026Pooled it
- Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review.PharmacoEconomics · 2024Pooled it
- Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review.Infectious diseases of poverty · 2023Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspective.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Article
- Effect of Remdesivir on Mortality in Mechanically Ventilated COVID-19 Patients: A Target Trial Emulation Using Inverse Probability of Treatment Weighting.Infection and drug resistance · 2026Article
- Translational Success and Pharmacoeconomic Lessons of Pandemic-Driven Drug Repurposing.Cureus · 2025Review
- An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025Article
- Natural and Designed Cyclic Peptides as Potential Antiviral Drugs to Combat Future Coronavirus Outbreaks.Molecules (Basel, Switzerland) · 2025Review
- Drug repurposing of argatroban, glimepiride and ranolazine shows anti-SARS-CoV-2 activity via diverse mechanisms.Heliyon · 2025Article
- COVID-19-related health utility values and changes in COVID-19 patients and the general population: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Evidence of quality of life for hospitalised patients with COVID-19: a scoping review.Health technology assessment (Winchester, England) · 2024Article
- Clinical trials and their impact on policy during COVID-19: a review.Wellcome open research · 2024Review
- Owner experience and veterinary involvement with unlicensed GS-441524 treatment of feline infectious peritonitis: a prospective cohort study.Frontiers in veterinary science · 2024Article
- Remdesivir: A Review in COVID-19.Drugs · 2023Review
- Dicoumarol is an effective post-exposure prophylactic for SARS-CoV-2 Omicron infection in human airway epithelium.Signal transduction and targeted therapy · 2023Article
- mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.Vaccine · 2023Article
- Economic evaluation of strategies against coronavirus: a systematic review.Health economics review · 2023Review
- The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing and reimbursement efforts.
methodsA Markov model evaluated the cost-effectiveness of remdesivir in patients hospitalized with COVID-19 from a US healthcare sector perspective. A lifetime time horizon captured potential long-term costs and outcomes. Model outcomes included discounted total costs, life-years, and quality-adjusted life-years (QALYs). Remdesivir was modeled as an addition to standard of care and compared with standard of care alone, including dexamethasone for patients requiring respiratory support. COVID-19 hospitalizations were assumed to be reimbursed through a single payment based on the respiratory support received alongside a remdesivir carveout payment in the base case. Sensitivity and scenario analyses identified key drivers.
resultsAt a unit price of $520 per vial and assuming no survival benefit with remdesivir, the incremental cost-effectiveness was $298 200/QALY for patients with moderate to severe COVID-19 and $1 847 000/QALY for patients with mild COVID-19. Although current data do not support a survival benefit, if one was assumed, the cost-effectiveness estimate was $50 100/QALY for the moderate to severe population and $103 400/QALY for the mild population. Another key driver included the hospitalization payment structure (per diem vs bundled payment).
conclusionsWith the current evidence available, remdesivir's price is too high to align with its expected health gains for hospitalized patients with COVID-19. Results from this study provide a rationale for iterative health technology assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.